Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study

Abstract Introduction Teclistamab is an established standard of care for the treatment of relapsed/refractory multiple myeloma (RRMM) based on MajesTEC-1 study results. United States (US)-based real-world studies of teclistamab treatment have had limited follow-up, were conducted in academic setting...

Descrición completa

Detalles Bibliográficos

Principais autores:	Binod Dhakal, Moshe Y. Levy, Gilbert Ko, Jinghua He, Nina Kim, Wenze Tang, Tonya Le Blanc, Jessica Fowler, Sarah Lucht, Madison Brown, Emily Bland, Camryn Craig, Sarah Giegerich, JaLyna Laney, Bruce Feinberg, Niodita Gupta-Werner, Shuchita Kaila, Peter Voorhees
Formato:	Artigo
Idioma:	Inglês
Publicado:	Adis, Springer Healthcare 2026-03-01
Series:	Oncology and Therapy
Assuntos:	Multiple myeloma Teclistamab Community oncology Real-world
Acceso en liña:	https://doi.org/10.1007/s40487-026-00429-8
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!